Overview

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Retapamulin